|
Jul 25
|
Edwards loses longtime TAVR leader Larry Wood
|
|
Jul 24
|
PROCEPT BioRobotics® President and CEO Dr. Reza Zadno to Retire, Company Appoints Larry L. Wood as New President and CEO
|
|
Jul 23
|
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
|
|
Jul 21
|
PROCEPT BioRobotics® to Report Second Quarter 2025 Financial Results on August 6, 2025
|
|
Jul 15
|
Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
|
|
Mar 24
|
WATER III Randomized-Controlled Trial Results Announced at European Association of Urology Comparing Aquablation® Therapy to Laser Enucleation
|
|
Feb 13
|
Procept BioRobotics Corp. (PRCT): Among the Best Mid-Cap Growth Stocks to Buy According to Analysts
|
|
Oct 9
|
PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
|
|
Oct 8
|
PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer
|
|
Oct 8
|
PROCEPT BioRobotics wins FDA IDE for aquablation trial in prostate cancer
|
|
Oct 7
|
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer
|
|
Oct 5
|
PROCEPT BioRobotics Corporation (PRCT) Advances Urology with AI-Integrated HYDROS Robotic System; Price Target Raised to $99
|
|
Sep 25
|
Is Procept Biorobotics Corp. (PRCT) the Worst AI Stock to Buy?
|
|
Aug 30
|
Do You Believe in the Growth Prospects of PROCEPT BioRobotics (PRCT)?
|
|
Aug 28
|
PROCEPT BioRobotics to Present at Upcoming 2024 Wells Fargo Healthcare Conference on September 4, 2024
|
|
Jul 24
|
With 84% ownership of the shares, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is heavily dominated by institutional owners
|
|
Jun 17
|
PROCEPT BioRobotics Announces New CPT® Category I Code from the American Medical Association for Aquablation therapy
|
|
May 13
|
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
|
|
May 6
|
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia
|
|
May 4
|
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported And Analysts Have Been Lifting Their Price Targets
|